Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Meta Analysis
Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Bevacizumab is a treatment option in patients with metastatic breast cancer. Congestive heart failure (CHF) has been reported, although the overall incidence and relative risk (RR) of this complication remains unclear. We performed an up-to-date, comprehensive meta-analysis to determine the risk of serious CHF in patients with breast cancer receiving bevacizumab. ⋯ This is the first comprehensive report to show that bevacizumab is associated with an increased risk of significant heart failure in patients with breast cancer.